GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Biological: albiglutide + insulin glargineDrug: insulin glargine + preprandial lispro insulin
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 586
- Registration Number
- NCT00976391
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom
Clinical Study to Test a New Drug to Treat Major Depression
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 128
- Registration Number
- NCT00976560
- Locations
- 🇷🇺
GSK Investigational Site, St-Petersburg, Russian Federation
Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults
- Conditions
- Influenza
- Interventions
- Biological: GSK investigational vaccine GSK2340272A
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 312
- Registration Number
- NCT00975884
- Locations
- 🇫🇷
GSK Investigational Site, Poitiers, France
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612
- Conditions
- Infections, Meningococcal
- Interventions
- Procedure: Blood Sampling
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 697
- Registration Number
- NCT00974363
- Locations
- 🇵🇭
GSK Investigational Site, Muntinlupa, Philippines
A Study of GW685698X in Healthy Japanese Male Subjects
- First Posted Date
- 2009-09-07
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00972673
- Locations
- 🇯🇵
GSK Investigational Site, Kagoshima, Japan
723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- First Posted Date
- 2009-09-07
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT00972504
- Locations
- 🇩🇪
GSK Investigational Site, Hannover, Niedersachsen, Germany
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
- Conditions
- Influenza
- Interventions
- Biological: GSK investigational vaccine GSK2340272A
- First Posted Date
- 2009-09-07
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 245
- Registration Number
- NCT00972517
- Locations
- 🇩🇪
GSK Investigational Site, Worms, Rheinland-Pfalz, Germany
Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose
- Conditions
- AIDS
- Interventions
- Biological: GSK Biologicals' HIV vaccine (732461)
- First Posted Date
- 2009-09-07
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00972725
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
Dose-Escalation Study of GSK2126458
- First Posted Date
- 2009-09-07
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 79
- Registration Number
- NCT00972686
- Locations
- 🇳🇱
GSK Investigational Site, Utrecht, Netherlands
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
- Conditions
- Influenza
- Interventions
- Biological: Pandemrix (GSK investigational influenza GSK2340272A vaccine)Biological: Fluarix™Biological: Placebo
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 145
- Registration Number
- NCT00971425
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany